July 13, 2024
Critical Limb Ischemia Treatment Market

Critical Limb Ischemia Treatment Market to Gain Traction Owing to Advances in Angioplasty Procedures

Critical limb ischemia (CLI) refers to a severe blockage in the arteries that reduces blood flow to the limbs. CLI treatment aims to restore blood flow in order to avoid limb amputation. Some of the key therapies for CLI treatment include angioplasty, bypass surgery, and thrombolytic therapy. Angioplasty procedures such as balloon angioplasty are minimally invasive and involve inserting a tiny inflatable balloon to widen narrowed or blocked arteries. Advances in angioplasty technologies such as drug-coated balloons and stents are estimated to drive the adoption of these procedures over invasive surgeries for CLI treatment.

The Global Critical Limb Ischemia Treatment Market is estimated to be valued at US$ 9.11 Bn in 2024 and is expected to exhibit a CAGR of 8.5% over the forecast period 2024 to 2031.

Key Takeaways

Companies operating in the Critical Limb Ischemia Treatment Market Share are Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Cook Medical Inc., Cardiovascular Systems, Inc., Philips Healthcare, B. Braun Melsungen AG, Terumo Corporation, Biotronik SE & Co. KG, Cordis Corporation, Smith & Nephew plc, Stryker Corporation, AngioDynamics, Inc., GE Healthcare, Sanofi S.A., AstraZeneca plc, and Bristol-Myers Squibb Company.

The key opportunities in the market include increasing adoption of minimally invasive procedures and rapid adoption of drug-coated balloons and stents. Advances in angioplasty technologies are further driving the adoption of endovascular therapies over open surgeries.

Market drivers: The increasing prevalence of peripheral artery disease (PAD) and diabetes mellitus globally is a major market driver. PAD affects over 200 million people worldwide and is a major cause of CLI. The risk of CLI is 10-15 times higher in diabetics compared to non-diabetics. Thus, the rising diabetes burden worldwide will likely increase the number of CLI cases, driving market growth over the forecast period.

Current Challenges in Critical Limb Ischemia Treatment Market

The Critical Limb Ischemia Treatment Market Share is facing challenges due to growing technological advancements, high cost of treatment and lack of awareness. Significant rise in diabetic patients population worldwide has increased the prevalence of peripheral arterial disease and critical limb ischemia. However, the treatment cost of critical limb ischemia poses a major challenge. Advanced treatment therapies such as drug-coated balloons and lipid-coated paclitaxel devices are expensive. Lack of sufficient reimbursement policies also hinders patients from opting for high cost treatment options. Additionally, lack of adequate infrastructure in developing regions limits optimal critical limb ischemia care. The market also faces challenges due to shortage of skilled professionals and surgeons for performing revascularization procedures. Raising awareness about warning signs of critical limb ischemia and available treatment options is crucial to overcome such challenges.

SWOT Analysis

Strength: Advanced treatment devices and drug-coated balloons offer minimally invasive treatment and better patient outcomes.

Weakness: High cost of treatment limits access.

Opportunity: Rising geriatric population increases patient pool.

Threats: Reimbursement hurdles and lack of infrastructure in developing regions pose threats.

Geographical Regions

North America currently dominates the critical limb ischemia treatment market in terms of value, owing to high treatment cost and rapid adoption of advanced technologies. The U.S. accounts for the major share due to presence of sophisticated healthcare infrastructure and favorable reimbursement policies.

Asia Pacific is poised to be the fastest growing regional market during the forecast period. Factors such as improving healthcare infrastructure, rising medical tourism and growing incidence of diabetes and peripheral arterial diseases will drive the Asia Pacific critical limb ischemia treatment market. Countries such as India, China and Japan are projected to provide lucrative opportunities for market players in the coming years.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Vaagisha Singh

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. LinkedIn

 

About Author - Vaagisha Singh

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. LinkedIn  

View all posts by About Author - Vaagisha Singh →